# EDGAR Filing Document

**Accession Number:** 0001757499
**File Stem:** 0001493152-25-029361
**Filing Date:** 2025-12
**Character Count:** 15913
**Document Hash:** 1985b7a61cfe832c6a5458f41c30cae5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-029361.hdr.sgml**: 20251229

**ACCESSION NUMBER**: 0001493152-25-029361

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251229

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251229

**DATE AS OF CHANGE**: 20251229

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shuttle Pharmaceuticals Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001757499
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41488
- **FILM NUMBER:** 251609172

**BUSINESS ADDRESS:**
- **STREET 1:** 401 PROFESSIONAL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879
- **BUSINESS PHONE:** (240) 403-4212

**MAIL ADDRESS:**
- **STREET 1:** 401 PROFESSIONAL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 29, 2025 (December 23, 2025)**

**SHUTTLE PHARMACEUTICALS HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

<u>Delaware</u> <u>001-41488</u> <u>82-5089826</u> <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

(240) 430-4212

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock $0.00001 per share | SHPH | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

On December 23, 2025 (the "<u>Effective</u> <u>Date</u>"), Shuttle Pharmaceuticals Holdings, Inc. (the "<u>Company</u>") entered into a First Amendment (the "<u>Amendment</u>") to Asset Purchase Agreement (the "<u>Agreement</u>") with 1563868 B.C. Ltd., a Canadian limited corporation and the Company's wholly owned subsidiary ("<u>Purchaser</u>"), 1542770 BC Ltd., a Canadian limited corporation ("<u>Seller</u>"), and ZhiTian (Andy) Zhang, an individual residing in Vancouver, Canada ("<u>Seller Guarantor</u>"), dated as of November 20, 2025.

Pursuant to the terms and conditions of the Amendment, on the Effective Date, the Company made an accelerated issuance of 320,496 shares of Company Common Stock as payment of a portion of the First Installment Payment (as defined in the Agreement). The Parties agreed that the remaining portion of the First Installment Payment not satisfied by such accelerated issuance would be paid in cash only in accordance with the terms of the Agreement.

The closing of the transactions contemplated under the Amendment were consummated on the Effective Date.

The aggregate number of shares of Company Common Stock issued to Seller on the effective date was 320,496 shares, representing 19.99% of the issued and outstanding shares of Company Common Stock as of the closing date of the Agreement, at a value of $1.76 per share (which value was calculated in accordance with the terms of the Agreement).

The Amendment contains customary representations, warranties and covenants that were made solely for the benefit of the parties to the Amendment.

The foregoing description of the Amendment is qualified by reference to the full text of the Amendment, with confidential portions redacted, as applicable, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by this reference.

**Item 3.02 Unregistered Sales of Equity Securities.**

The information set forth under in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The issuance of Company Common Stock, if and when issued pursuant to the terms of the Agreement, will not be registered under the Securities Act and will instead be offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Rule 506(b) promulgated thereunder and Rule 903 of Regulation S under the Securities Act.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1\* | [First Amendment to Asset Purchase Agreement, dated as of December 23, 2025, by and among Shuttle Pharmaceuticals Holdings, Inc.,1563868 B.C. Ltd., 1542770 BC Ltd., and Zhitian (Andy) Zhang.](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\* Schedules and exhibits omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule to the Securities and Exchange Commission upon request.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | SHUTTLE PHARMACEUTICALS HOLDINGS, INC. |
| Dated: December 29, 2025 |  |  |
|  | By: | */s/ Christopher Cooper* |
|  | Name: | Christopher Cooper |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

EXECUTION COPY

**FIRST AMENDMENT TO**

**ASSET PURCHASE AGREEMENT**

This Amendment to Asset Purchase Agreement (this "***Amendment***") is made and entered into as of December 23, 2025 (the "***Effective Date***"), by and among Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation ("***Parent***"), 1563868 B.C. Ltd., a Canadian limited corporation ("***Purchaser***"), 1542770 BC Ltd., a Canadian limited corporation ("***Seller***") and ZhiTian (Andy) Zhang, an individual residing in Vancouver, Canada ("***Seller Guarantor***") (Parent, Purchaser, Seller and Seller Guarantor are collectively referred to herein as the "***Parties***" and individually as a "***Party***").

**WHEREAS**, the Parties entered into that certain Asset Purchase Agreement, dated as of November 20, 2025 (the "***Agreement***"; capitalized terms used in this Amendment shall have the meanings indicated in the Agreement), contemplating Purchaser's purchase of all right, title and interest in and to the Transferred Assets and the Transferred Liabilities of the Business, upon the terms and subject to the conditions more particularly specified in the Agreement; and

**WHEREAS,** the Purchase Price contemplates the payment of the First Installment Payment on the 6 month anniversary of the signing of the Agreement; and

**WHEREAS**, the Parties desire to amend the Agreement to provide for the accelerated payment of a portion of the First Installment Payment through the issuance, as of the Effective Date, of shares of Parent Common Stock representing 19.99% of the issued and outstanding shares of Parent Common Stock as of the Closing Date; and

**WHEREAS**, the Parties further desire to amend the Agreement to provide that the remaining portion of the First Installment Payment not satisfied by such accelerated issuance be paid in cash only, in accordance with the terms of the Agreement; and

**WHEREAS**, the Parties wish to modify the Agreement solely to the extent set forth herein, and otherwise to reaffirm all other terms, conditions, rights and obligations under the Agreement.

**NOW, THEREFORE**, in consideration of the mutual promises contained in this Amendment and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1. <u>Amendment to Agreement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a. The following definitions shall be inserted in alphabetical order in Section 1.1:

""<u>Accelerated Issuance</u>" shall mean 320,496 shares of Parent Common Stock, representing 19.99% of all issued and outstanding shares of Parent Common Stock as of the Closing Date."

""<u>Accelerated Issuance Date</u>" shall mean December 23, 2025."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The definition of "First Installment Payment" in Section 1.1 of the Agreement is hereby deleted in its entirety and replaced with the following:

""<u>First Installment Payment</u>" shall mean $2,435,927.64, payable in cash."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The definition of "Installment Payments" in Section 1.1 of the Agreement is hereby deleted in its entirety and replaced with the following:

""<u>Installment Payments</u>" shall mean the Accelerated Issuance, the First Installment Payment and the Second Installment Payment."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Section 3.1 (Purchase Price) of the Agreement is hereby deleted in its entirety and replaced with the following:

"3.1 <u>Purchase Price</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. On the terms and subject to the conditions set forth herein, the consideration payable in respect of the sale, assignment and delivery of the Transferred Assets (the "<u>Purchase Price</u>") shall be (i) an amount in cash equal to the Closing Cash Consideration, payable on the Closing Date; (ii) the Accelerated Issuance, payable on the Accelerated Issuance Date; (iii) the First Installment Payment, payable on the 6 month anniversary of the Closing Date; (iv) the Second Installment Payment, payable on the one year anniversary of the Closing Date; (v) the contingent right to receive the Contingent Payments in accordance with Section 3.4; and (vi) the assumption of the Transferred Liabilities, which clauses (i) through (vi) above, collectively, shall comprise the total consideration to be paid for the Transferred Assets. The Parties acknowledge that Purchaser will not be assuming any Excluded Liabilities and that Seller will remain responsible for all Excluded Liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. On the Closing Date, Purchaser or its designee shall deliver an amount in cash to Seller equal to the Closing Cash Consideration. On the Accelerated Issuance Date, Parent shall deliver the Accelerated Issuance to Seller. On the 6 month anniversary of the Closing Date, Purchaser or its designee shall deliver an amount of cash to Seller equal to the First Installment Payment. On the one year anniversary of the Closing Date, Purchaser or its designee shall deliver to Seller an amount of cash and/or Parent Common Stock to Seller equal to the Second Installment Payment."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. Section 3.2 ([Reserved]) of the Agreement is hereby deleted in its entirety and replaced with the following:

"3.2 <u>Accelerated Issuance</u>. Notwithstanding anything to the contrary set forth herein, and consistent with Section 3.5 hereof, neither Purchaser nor Parent shall be obligated to pay or issue, and Seller shall have no right to elect to receive, any shares of Parent Common Stock or other equity securities as payment of, or in lieu of, any portion or all of the First Installment Payment in excess of 19.99% of issued and outstanding shares of Parent Common Stock as of the date of such issuance without first obtaining approval of Parent's stockholders."

2. <u>Effect of Amendment</u>. From and after the Effective Date, each reference in the Agreement to "this Agreement," "hereunder," "hereof," "herein," or words of like import, and each reference in any other Transaction Document to the Agreement, shall be deemed to refer to the Agreement as amended by this Amendment.

3. <u>Ratification</u>. Each Party hereby reaffirms all of its respective covenants, agreements, obligations, representations and warranties under the Agreement, as amended hereby, and acknowledges and agrees that, after giving effect to this Amendment, the Agreement remains in full force and effect and is the legal, valid and binding obligation of such Party, enforceable in accordance with its terms.

4. <u>No Other Modification</u>. Except as specifically amended by the terms of this Amendment, this Amendment shall not constitute a waiver, amendment or modification of any provision of the Agreement and all other terms and conditions set forth in the Agreement shall remain in full force and effect.

5. <u>Miscellaneous</u>. The provisions of Sections 11.1 through 11.10 and 11.13 through 11.18 of the Agreement are hereby incorporated by reference into this Amendment, *mutatis mutandis*, as if fully set forth herein, and shall govern this Amendment.

6. <u>Entire Agreement</u>. This Amendment, together with the Agreement and the Transaction Documents, contains the entire agreement and understanding of the parties hereto with respect to the subject matter contained therein and may not be contradicted by evidence of any alleged oral agreement.

7. <u>Further Assurances</u>. Each party to this Amendment agrees to perform any further acts and execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Amendment.

[*Remainder of Page Intentionally Left Blank*]

**IN WITNESS WHEREOF**, the parties hereto have duly executed this Amendment to be effective for all purposes as of the date first above written.

---

| | |
|:---|:---|
| **SHUTTLE PHARMACEUTICALS HOLDINGS, INC.** | **SHUTTLE PHARMACEUTICALS HOLDINGS, INC.** |
| By: | */s/ Chris Cooper* |
| Name: | Christopher Cooper |
| Title: | CEO |
| **1563868 B.C. LTD.** | **1563868 B.C. LTD.** |
| By: | */s/ Chris Cooper* |
| Name: | Christopher Cooper |
| Title: | President |
| **1542770 BC LTD.** | **1542770 BC LTD.** |
| By: | */s/ ZhiTian (Andy) Zhang* |
| Name: | ZhiTian (Andy) Zhang |
| Title: | Authorized Signatory |
|  | */s/ ZhiTian (Andy) Zhang* |
| Name: | ZhiTian (Andy) Zhang |

---

[Signature Page to First Amendment to Asset Purchase Agreement]